<DOC>
	<DOCNO>NCT02941445</DOCNO>
	<brief_summary>Weight reduction important treatment target obese woman polycystic ovary syndrome ( PCOS ) , yet usually hardly achievable lifestyle intervention alone . Glucagon-like peptide 1 ( GLP-1 ) receptor agonist ( RA ) liraglutide recently approve anti-obesity drug limitation , include high cost lack long-term efficacy safety data regard weight reduction . In addition , weight loss achieve liraglutide often non-sustainable treatment cessation . Although DPP-4 inhibitor weight neutral , reduce weight regain animal previously treat GLP-1 RAs switch DPP-4 inhibitor rather placebo . The aim evaluate whether DPP-4 inhibitor sitagliptin combination metformin reduce body weight regain effectively metformin alone obese PCOS previously treat liraglutide .</brief_summary>
	<brief_title>Weight Maintenance With Dipeptidyl Peptidase 4 ( DPP4 ) Inhibitor Sitagliptin Combination With Metformin After Liragludite Induced Weight Loss</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>18 year old menopause polycystic ovary syndrome ( NICHD criterion ) BMI 30kg/m2 high type 1 type 2 diabetes mellitus history carcinoma Cushing 's syndrome congenital ( nonclassic ) adrenal hyperplasia personal family history multiple endocrine neoplasia type 2 significant cardiovascular , kidney hepatic disease use statins , within 90 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>DPP4-inhibitors</keyword>
</DOC>